There was no discussion of costs. The story included quantitive information about weight loss over time. It did not quantify the impact on blood pressure. The story mentioned specific side effects of this particular medication combination. To be most informative to readers, the story should have mentioned that the potential for long-term harm is not known. And the rate at which people stopped taking the drug due to side effects should have been included. While indicating that several studies had been conducted in more than 4,500 people with various characteristics, the story never mentioned whether the studies are considered definitive or not; it also did not mention that the results of these studies have not yet been published in peer-reviewed journals. And while reporting that weight loss appeared to be dose dependent, there was no discussion of how weight loss compared with those in control groups. Lastly – as the focus of the story appeared to be on an effect on blood pressure, it would seem that the story should have included some detail about the magnitude of the change. The story did not engage in overt disease mongering. The story mention that the study author and Dr. Aronne received funding from the manufacturer of this drug. It also included a quote from the president of the American Society of Hypertension who does not appear to have a financial tie to this product. There was no information about how well this product works in comparison with other approaches to weight loss. It’s pretty clear from the story that the combination of the two drugs is not yet available. The story reported that the drug was a combination of two commercially available medications. It does not appear that the story relied solely or largely on a news release.
Weight Loss Pill Also Lowers Blood Pressure